Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Oncology
- Publicado em
- 1 jul 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial
Koen P Rovers, Checca Bakkers, Teun B M van den Heuvel, Vincent C J van de Vlasakker, Teun M E Kerkhoff, Simon W Nienhuijs, Jacobus W A Burger, Geert-Jan M Creemers, Irene E G van Hellemond, Jurriaan B Tuynman et al.
Descritores MeSH
- Cytoreduction Surgical Procedures
- Antineoplastic Combined Chemotherapy Protocols
- Peritoneal Neoplasms
- Colorectal Neoplasms
- Adenocarcinoma
- Hyperthermic Intraperitoneal Chemotherapy
- Aged
- Adult
- Oxaliplatin
- Leucovorin
Veja também
Estudos relacionados
- Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial
- Preliminary analysis of mFOLFOXIRI plus bevacizumab combined with cytoreductive surgery for resectable peritoneal metastases from colorectal cancer: a prospective,randomized phase II clinical trial
- Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial